Clinical Oncology Study Section – CONC

Topics

• Therapeutic clinical trials including surgery, chemotherapy, radiation therapy and radiopharmaceuticals, and combination therapies.
• Treatment modalities include immunotherapy, vaccines therapeutics and prevention, gene therapy, and small molecular/targeted therapy.
• Pharmacologic and toxicological studies of new modalities in patients and correlative studies relevant to therapeutics clinical trials.
• Non-behavioral alternative cancer therapies, and the therapy and care of older cancer patients with age-specific issues.
• Validation of prognostic and/or predictive biomarkers/molecular signatures using large scale clinical samples.
• Cancer detection, monitoring of its progression or response to therapy using available medical imaging approaches including but not limited to MRI, PET, MRS, fluorescence, and immunohistochemical assays.

Shared Interests and Overlaps

There are shared interests with Molecular Cancer Diagnosis and Combination (MCDC) in the areas of clinical samples to validate for cancer detection and response to therapy. Applications that focus on the predictive and prognostic biomarkers using small scale samples may be reviewed in MCDC. Applications that focus on the validation of prognostic biomarkers using large scale clinical samples may be reviewed in CONC.

There are shared interests with Cellular Immunotherapy of Cancer (CIC) in the area of adaptive cellular therapies. Applications that focus on preclinical cellular immunotherapy and combination with immunotherapy/chemotherapy may be reviewed in CIC. Applications that focus on the cellular immunotherapy clinical trials and correlative studies may be reviewed in CONC.

There are shared interests with Therapeutic Immune Regulation (TIR) in the area of cancer clinical trial. Applications that focus on preclinical and early clinical studies of immunotherapy strategies may be reviewed in TIR. Applications that focus on therapeutic clinical trials including combined modality therapy may be reviewed in CONC.

There are shared interests with Radiation Therapeutics and Biology (RTB) in the area of radiation therapy. Applications that focus on therapeutic interactions of ionizing radiation, radionuclides, electromagnetic radiation, and heat at the molecular, cellular, organ and patient levels may be reviewed in RTB. Applications that focus on cancer clinical trials using radiopharmaceuticals or radiotherapy in combination therapy may be reviewed in CONC.

There are shared interests with Clinical Translational Imaging Science (CTIS) in imaging modalities. Applications that focus on the imaging system or protocol development in diagnosis of cancer or monitoring progression and response to therapy, the application may be reviewed in CTIS. Applications that focus on using imaging techniques to monitor therapeutic outcomes in clinical trials may be reviewed in CONC.

There are shared interests in early-stage, pilot clinical trials with Advancing Therapeutics (ATA). Applications that focus on clinical trials with targeted therapy of small molecular inhibitors are reviewed in CONC. Applications that focus on the experimental therapy of neoplastic diseases in in vitro systems and in vivo model systems, including some pilot clinical trials are reviewed in ATA.